FS 118

N/A

Report date: 2024/08/08 20:00:07

Base Information

Drug NameFS 118
Drug Alias NameFS118LAG-3/PD-L1 Bispecific AntibodyFS-118
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsProgrammed death-ligand 1 blockers
TargetsLymphocyte activation gene 3 proteinProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasm MetastasisSquamous Cell Carcinoma of Head and NeckNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck SeronoF-Star
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInvoX Pharma Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisSquamous Cell Carcinoma of Head and NeckNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A